GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35
Multiple sclerosis (MS) still lacks reliable biomarkers of neuroinflammation predictive for disease activity and treatment response. Thus, in a prospective study we assessed 55 MS patients (28 interferon (IFN)-treated, 10 treated with no-IFN therapies, 17 untreated) and 20 matched healthy controls (...
Guardado en:
Autores principales: | Roberto De Masi, Stefania Orlando |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cf5ad9c582db4e58845a5c6cfa3c41cd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review
por: Sylwia Pietrasik, et al.
Publicado: (2021) -
Multiple sclerosis international
Publicado: (2010) -
TRPM2 contributes to neuroinflammation and cognitive deficits in a cuprizone-induced multiple sclerosis model via NLRP3 inflammasome
por: Yu Shao, et al.
Publicado: (2021) -
Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis
por: Jagadeswara Rao Earla, et al.
Publicado: (2021) -
Primary Peripheral Epstein-Barr Virus Infection Can Lead to CNS Infection and Neuroinflammation in a Rabbit Model: Implications for Multiple Sclerosis Pathogenesis
por: Asma Hassani, et al.
Publicado: (2021)